Clinical Trial Detail

NCT ID NCT02054520
Title Immunotherapy Study for Patients With Stage IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors NewLink Genetics Corporation
Indications

melanoma

Therapies

Ipilimumab

Age Groups: adult

No variant requirements are available.